Thylakoids for Health & Longevity - Quick Reference Sheet

Thylakoids for Health & Longevity

Created on 08/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Green membranes concentrated from spinach, taken before meals to slow fat digestion and trigger fullness signals. The clearest effect is greater fullness and less hunger for hours after eating. Weight-loss evidence is weak and conflicting. A low-risk, food-derived aid to eating well, with mainly mild digestive effects and untested long-term safety. (Full Review)

Protocol

Dose
~5 g
Standardized spinach thylakoid powder in water, a smoothie, or yogurt
Timing
Before a meal
Breakfast or lunch containing some fat
Frequency
Once daily
Single pre-meal dose; some use it before more than one meal
Time to effect
Fullness & appetite
Acute
Felt within the first meal or two after dosing
Weight & body fat
Weeks to 3 months
Accrues over several weeks to 3 months of daily use
Cravings
Several weeks
Reduced over several weeks of daily use

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Children (<18 years)
  • Active eating disorders
  • History of calcium-oxalate kidney stones
  • Fat-malabsorption disorders
  • Warfarin without INR monitoring
Key Interactions
  • Vitamin K–antagonist anticoagulants (warfarin)
  • Antidiabetic drugs (insulin, sulfonylureas)
  • Orlistat
  • Fat-soluble vitamins (A, D, E, K), carotenoids, oil-based supplements
  • GLP-1 receptor agonists (semaglutide)

Risk & Side Effects

  • High: Mild gastrointestinal effects
  • Medium: Reduced absorption of dietary fat and fat-soluble nutrients
  • Low: Vitamin K–related anticoagulant interference; oxalate load and kidney stone risk
  • Speculative: Unknown long-term effects of chronic use

Monitoring

Marker Target Why
Body weight / waist circumference Waist <94 cm (men), <80 cm (women) Primary intended outcome
Fasting glucose 70–85 mg/dL Glucose handling
HbA1c <5.4% Average glucose over ~3 months
Fasting insulin <6 µIU/mL Insulin resistance
LDL cholesterol <100 mg/dL (lower if higher risk) Modest lipid changes reported in trials
Triglycerides <80 mg/dL Dietary fat handling
INR (if on warfarin) Individualized (commonly 2.0–3.0) Vitamin K–driven anticoagulation stability
Vitamin D (25-OH) 40–60 ng/mL Fat-soluble vitamin status with long-term use

Cadence: Weight, waist, and appetite/cravings at ~4 and 12 weeks; glucose, insulin, and lipids at ~3 months, then every 6–12 months; INR within 1–2 weeks of starting for anticoagulant users.

Qualitative Assessment

  • Hunger and fullness: Whether meals feel more satisfying and hunger between meals is reduced
  • Cravings: Reduced urge for sweets, snacks, and palatable foods, especially afternoon and evening
  • Energy and eating patterns: Steadier daytime energy and fewer episodes of impulsive or reward-driven eating
  • Digestive comfort: Absence of bothersome loose stools, bloating, or flatulence at the chosen dose